Analysis and Commentary Guest User 9/8/12 Analysis and Commentary Guest User 9/8/12 Of 6-Month CRs and the Perils of Sequestration Read More Analysis and Commentary Guest User 8/24/12 Analysis and Commentary Guest User 8/24/12 Bringing IT at the FDA into the 21st Century Read More Analysis and Commentary Guest User 8/20/12 Analysis and Commentary Guest User 8/20/12 Relative -- as Opposed to Absolute -- Levels of FDA Funding Read More Analysis and Commentary Guest User 8/13/12 Analysis and Commentary Guest User 8/13/12 Honest assessment of priorities: a Congressional imperative for FDA Read More Analysis and Commentary Guest User 7/27/12 Analysis and Commentary Guest User 7/27/12 Potentially Increased Risk for Cutbacks as the Squeeze Tightens Read More Analysis and Commentary Guest User 7/20/12 Analysis and Commentary Guest User 7/20/12 Through the Crystal Ball Darkly Read More Analysis and Commentary Guest User 7/15/12 Analysis and Commentary Guest User 7/15/12 Sustaining FDA Remains a National Priority Read More Analysis and Commentary Guest User 6/28/12 Analysis and Commentary Guest User 6/28/12 A Delay Until July ... And What May Happen Read More Analysis and Commentary Guest User 6/28/12 Analysis and Commentary Guest User 6/28/12 It's Not a "Normal" Year ... And So ... Read More Analysis and Commentary Guest User 6/22/12 Analysis and Commentary Guest User 6/22/12 What If There's a Sequester? Read More Analysis and Commentary Guest User 6/10/12 Analysis and Commentary Guest User 6/10/12 The FDA's Best Case, Optimistic Scenario for FY 13 Read More Analysis and Commentary Guest User 6/1/12 Analysis and Commentary Guest User 6/1/12 Will Congress Actually Stand Behind its Own Words? Read More Analysis and Commentary Guest User 5/19/12 Analysis and Commentary Guest User 5/19/12 Pre-sequester Funding Situation for FDA in FY 13 Getting Clearer Read More Analysis and Commentary Guest User 5/11/12 Analysis and Commentary Guest User 5/11/12 Preliminary Positioning and the 2013 Budget Cuts: The FDA Should Remain an Exception Read More Analysis and Commentary Guest User 5/4/12 Analysis and Commentary Guest User 5/4/12 Why Commissioner Hamburg is Already Talking About the FY 14 Budget Read More Analysis and Commentary, Uncategorized Guest User 4/30/12 Analysis and Commentary, Uncategorized Guest User 4/30/12 Senate Appropriations Committee Adopts $24 Million Increase for FDA Read More Analysis and Commentary Guest User 4/23/12 Analysis and Commentary Guest User 4/23/12 FDA Appropriations Off to a Fast Start Read More Analysis and Commentary Guest User 4/13/12 Analysis and Commentary Guest User 4/13/12 FDA's Proposed BA and User Fee Funding for FY 13 Read More Analysis and Commentary Guest User 4/6/12 Analysis and Commentary Guest User 4/6/12 The Elevator Speech ... How the Alliance (and You) Can Make Our Points on the Hill Read More Analysis and Commentary Guest User 3/30/12 Analysis and Commentary Guest User 3/30/12 "More of the Same" and Yet "Entirely Different" Read More Newer Posts Older Posts
Analysis and Commentary Guest User 9/8/12 Analysis and Commentary Guest User 9/8/12 Of 6-Month CRs and the Perils of Sequestration Read More
Analysis and Commentary Guest User 8/24/12 Analysis and Commentary Guest User 8/24/12 Bringing IT at the FDA into the 21st Century Read More
Analysis and Commentary Guest User 8/20/12 Analysis and Commentary Guest User 8/20/12 Relative -- as Opposed to Absolute -- Levels of FDA Funding Read More
Analysis and Commentary Guest User 8/13/12 Analysis and Commentary Guest User 8/13/12 Honest assessment of priorities: a Congressional imperative for FDA Read More
Analysis and Commentary Guest User 7/27/12 Analysis and Commentary Guest User 7/27/12 Potentially Increased Risk for Cutbacks as the Squeeze Tightens Read More
Analysis and Commentary Guest User 7/20/12 Analysis and Commentary Guest User 7/20/12 Through the Crystal Ball Darkly Read More
Analysis and Commentary Guest User 7/15/12 Analysis and Commentary Guest User 7/15/12 Sustaining FDA Remains a National Priority Read More
Analysis and Commentary Guest User 6/28/12 Analysis and Commentary Guest User 6/28/12 A Delay Until July ... And What May Happen Read More
Analysis and Commentary Guest User 6/28/12 Analysis and Commentary Guest User 6/28/12 It's Not a "Normal" Year ... And So ... Read More
Analysis and Commentary Guest User 6/22/12 Analysis and Commentary Guest User 6/22/12 What If There's a Sequester? Read More
Analysis and Commentary Guest User 6/10/12 Analysis and Commentary Guest User 6/10/12 The FDA's Best Case, Optimistic Scenario for FY 13 Read More
Analysis and Commentary Guest User 6/1/12 Analysis and Commentary Guest User 6/1/12 Will Congress Actually Stand Behind its Own Words? Read More
Analysis and Commentary Guest User 5/19/12 Analysis and Commentary Guest User 5/19/12 Pre-sequester Funding Situation for FDA in FY 13 Getting Clearer Read More
Analysis and Commentary Guest User 5/11/12 Analysis and Commentary Guest User 5/11/12 Preliminary Positioning and the 2013 Budget Cuts: The FDA Should Remain an Exception Read More
Analysis and Commentary Guest User 5/4/12 Analysis and Commentary Guest User 5/4/12 Why Commissioner Hamburg is Already Talking About the FY 14 Budget Read More
Analysis and Commentary, Uncategorized Guest User 4/30/12 Analysis and Commentary, Uncategorized Guest User 4/30/12 Senate Appropriations Committee Adopts $24 Million Increase for FDA Read More
Analysis and Commentary Guest User 4/23/12 Analysis and Commentary Guest User 4/23/12 FDA Appropriations Off to a Fast Start Read More
Analysis and Commentary Guest User 4/13/12 Analysis and Commentary Guest User 4/13/12 FDA's Proposed BA and User Fee Funding for FY 13 Read More
Analysis and Commentary Guest User 4/6/12 Analysis and Commentary Guest User 4/6/12 The Elevator Speech ... How the Alliance (and You) Can Make Our Points on the Hill Read More
Analysis and Commentary Guest User 3/30/12 Analysis and Commentary Guest User 3/30/12 "More of the Same" and Yet "Entirely Different" Read More
